Adding tamper resistant properties to medications can help curb prescription drug abuse

NewsGuard 100/100 Score

Health Canada today published a Notice of Pre-Consultation in Canada Gazette, Part I, seeking stakeholder feedback on draft Tamper-Resistant Properties of Drugs Regulations. The draft regulations would require that all controlled release oxycodone products have tamper-resistant properties before they can be sold in Canada.

These draft regulations build upon the numerous initiatives the Government is supporting to combat prescription drug abuse. The Government of Canada invests approximately $130 million a year to address addictions and drug abuse in Canada under the National Anti-Drug Strategy. These funds contribute to developing tangible and effective solutions to the problems of drug addiction. In 2014, the government committed over $44 million over five years to expand the focus of the National Anti-Drug Strategy from illicit drugs to include measures to address prescription drug abuse.

Over the past several months, the Government of Canada has taken a number of steps to address prescription drug abuse, including:

  • launching a national marketing campaign to equip parents with the information and tools needed to talk with their teenagers about the harmful effects of prescription drug abuse;
  • providing $13.5 million over five years to enhance prevention and treatment services for prescription drug abuse in First Nations communities;
  • launching the Canadian Research Initiative in Substance Misuse (CRISM), a national research network aimed at improving the health of Canadians living with substance misuse;
  • announcing nearly $8 million to support projects to improve prescriber education and to support the development of a national approach to the monitoring and surveillance of prescription drugs,
  • announcing nearly $13 million over five years to increase the number of annual pharmacy inspections carried out by Health Canada; and,
  • releasing four promotional videos featuring personal stories from Canadians directly affected by prescription drug abuse.

Quick Facts

  • Canada is the world's second largest per capita consumer of prescription opioids.
  • In 2013, 22% of Canadians aged 15 and older reported using a psychoactive prescription drug. Of these, 2% (about 146,000) reported abusing the drug for non-medical purposes.
  • A comprehensive study on prescription drug abuse by the Standing Committee on Health (HESA) recommended the Government consider the merits of tamper-resistant drugs in addressing prescription drug abuse.
  • On May 15, 2015, the Minister of Health attended the Prescribing Practices Forum in Hamilton, Ontario, bringing together regulatory authorities, health professionals and experts in the field to identify steps to improve prescribing practices, with the ultimate goal of reducing the abuse of prescription drugs.
  • Minister Ambrose hosted a productive symposium on prescription drug abuse in Edmonton on May 19, 2015, where she met with provincial officials, doctors, pharmacists, First Nations representatives, law enforcement and addictions specialists to discuss current challenges, best practices and areas for further action under the National Anti-Drug Strategy.

Quotes

"Prescription drug abuse is a significant public health and safety concern. Adding tamper resistant properties to drugs at high risk of abuse is an important component of our Government's comprehensive approach to fighting prescription drug abuse."
Rona Ambrose
Minister of Health

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Examining how pain could play a direct protective role in the gut